301 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
51 | 26551887 | The cyclic GMP/protein kinase G pathway as a therapeutic target in head and neck squamous cell carcinoma. | 2016 Jan 28 | 2 |
52 | 26620458 | Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update. | 2016 Sep-Oct | 1 |
53 | 26676726 | [Pharmacological treatment of benign prostatic hyperplasia]. | 2016 Jan | 1 |
54 | 27337189 | Isolation and structural characterization of a new tadalafil analog (chloropropanoylpretadalafil) found in a dietary supplement. | 2016 Sep 5 | 1 |
55 | 27418235 | Inhibition of Adrenergic and Non-Adrenergic Smooth Muscle Contraction in the Human Prostate by the Phosphodiesterase 10-Selective Inhibitor TC-E 5005. | 2016 Nov | 1 |
56 | 27440770 | BET 2: Tadalafil medical expulsive therapy in ureteral calculi: a new kid on the block? | 2016 Aug | 2 |
57 | 27871960 | Useful Implications of Low-dose Long-term Use of PDE-5 Inhibitors. | 2016 Jul | 1 |
58 | 27928428 | Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia. | 2016 Aug | 1 |
59 | 28163539 | Inhibition by tadalafil of contractility of isolated nonpregnant human myometrium. | 2016 Oct-Dec | 1 |
60 | 25318865 | Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension. | 2015 Feb | 2 |
61 | 25320361 | Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma. | 2015 Jan 1 | 1 |
62 | 25352458 | Effects of PDE type 5 inhibitors on left ventricular diastolic dysfunction in resistant hypertension. | 2015 Jan | 2 |
63 | 25444755 | PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer. | 2015 Mar | 4 |
64 | 25462127 | Isolation and structural characterization of a new tadalafil analog (2-hydroxyethylnortadalafil) found in a dietary supplement. | 2015 Jan 25 | 1 |
65 | 25564570 | Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma. | 2015 Jan 1 | 1 |
66 | 25744459 | Contribution of CYP3A isoforms to dealkylation of PDE5 inhibitors: a comparison between sildenafil N-demethylation and tadalafil demethylenation. | 2015 | 2 |
67 | 25801159 | Discovery of novel pyrazolopyrimidinone analogs as potent inhibitors of phosphodiesterase type-5. | 2015 May 1 | 1 |
68 | 25981401 | Effects of phosphodiesterase-5 inhibitor on ischemic kidney injury during nephron sparing surgery: quantitative assessment by NGAL and KIM-1. | 2015 Dec | 2 |
69 | 26047999 | [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. | 2015 Jul-Sep | 1 |
70 | 26060141 | Use of phosphodiesterase type 5 inhibitors in assistive living and home care settings. | 2015 Aug | 1 |
71 | 26161145 | Tadalafil therapy for erectile dysfunction following prostatectomy. | 2015 Jun | 1 |
72 | 26328208 | Current use of phosphodiesterase inhibitors in urology. | 2015 Jun | 1 |
73 | 26425140 | Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action. | 2015 Oct | 2 |
74 | 26962606 | 2015 Jul | 2 | |
75 | 23721687 | Screening of synthetic PDE-5 inhibitors and their analogues as adulterants: analytical techniques and challenges. | 2014 Jan | 1 |
76 | 23841532 | A return to normal erectile function with tadalafil once daily after an incomplete response to as-needed PDE5 inhibitor therapy. | 2014 Mar | 5 |
77 | 24271647 | Tadalafil-induced improvement in left ventricular diastolic function in resistant hypertension. | 2014 Feb | 2 |
78 | 24341303 | Tadalafil - a therapeutic option in the management of BPH-LUTS. | 2014 Jan | 3 |
79 | 24666765 | Effect of once-daily tadalafil on confidence and perceived difficulty in performing sexual intercourse in men who were incomplete responders to as-needed PDE5 inhibitor treatment. | 2014 Jul | 1 |
80 | 24717626 | Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. | 2014 Apr | 1 |
81 | 24796952 | Analysis of illicit dietary supplements sold in the Italian market: identification of a sildenafil thioderivative as adulterant using UPLC-TOF/MS and GC/MS. | 2014 May | 2 |
82 | 24808022 | PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy. | 2014 Jun 10 | 1 |
83 | 24878583 | Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma. | 2014 Aug | 1 |
84 | 24940471 | Sildenafil can induce the onset of a cluster headache bout. | 2014 May | 1 |
85 | 25140232 | Tadalafil in the management of lower urinary tract symptoms: a review of the literature and current practices in Russia. | 2014 | 1 |
86 | 25178687 | Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension. | 2014 Nov | 1 |
87 | 25202655 | Can selective inhibitors of cyclic guanosine monophosphate (cGMP)-specific phosphadiesterase type 5 (PDE 5) offer protection against contrast induced nephropathy? | 2014 Aug | 2 |
88 | 25322707 | Tadalafil prevents acute heart failure with reduced ejection fraction in mice. | 2014 Dec | 1 |
89 | 26583228 | Ab Initio QM/MM Study Shows a Highly Dissociated SN2 Hydrolysis Mechanism for the cGMP-Specific Phosphodiesterase-5. | 2014 Dec 9 | 1 |
90 | 22971615 | Combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-reponders with severe and intermediate testosterone deficiency. | 2013 Jan | 1 |
91 | 23065016 | Central serous chorioretinopathy due to tadalafil use. | 2013 Apr | 1 |
92 | 23253640 | Comparison of efficacy and satisfaction profile, between penile prosthesis implantation and oral PDE5 inhibitor tadalafil therapy, in men with nerve-sparing radical prostatectomy erectile dysfunction. | 2013 Jul | 1 |
93 | 23312193 | Re: combination therapy of testosterone enanthate and tadalafil on PDE5 inhibitor non-responders with severe and intermediate testosterone deficiency. | 2013 Feb | 1 |
94 | 23369145 | Managing erectile dysfunction in heart failure. | 2013 Mar | 1 |
95 | 23372609 | Avanafil for the treatment of erectile dysfunction: initial data and clinical key properties. | 2013 Feb | 2 |
96 | 23386068 | Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. | 2013 Feb | 1 |
97 | 23417046 | [Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors]. | 2013 Feb | 2 |
98 | 23441682 | Ca2+ -activated K+ channel (KCa) stimulation improves relaxant capacity of PDE5 inhibitors in human penile arteries and recovers the reduced efficacy of PDE5 inhibition in diabetic erectile dysfunction. | 2013 May | 1 |
99 | 23512808 | Title efficacy of phosphodiesterase 5 inhibitor on distant burn-induced muscle autophagy, microcirculation, and survival rate. | 2013 May 1 | 1 |
100 | 23529917 | Tadalafil: a phosphodiesterase-5 inhibitor for benign prostatic hyperplasia. | 2013 Jun | 1 |